
|Articles|September 18, 2014
- Melanoma (Issue 3)
- Volume 3
- Issue 1
Partnering T-VEC With a Targeted Agent for the Treatment of Melanoma
Author(s)Igor Puzanov, MD
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the potential to partner T-VEC with a targeted agent for the treatment of patients with melanoma.
Advertisement
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the potential to partner T-VEC with a targeted agent for the treatment of patients with melanoma.
Learn about targeted agents for the treatment of melanoma > >
Articles in this issue
over 11 years ago
Inducing an Immune Response With a Patient’s Tumorover 11 years ago
Immunotherapy Combinations for the Treatment of MelanomaAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















